Taking aim at disease

February 16, 2024, 3:02PMNuclear NewsKristi Nelson Bumpus
ORNL radioisotope manufacturing coordinator Jillene Sennon-Greene places a shipment vial of actinium-225 inside the dose calibrator to confirm its activity is within customer specifications. (Photo: Carlos Jones/ORNL, DOE)

On August 2, 1946, 1 millicurie of the isotope carbon-14 left Oak Ridge National Laboratory, bound for the Barnard Free Skin and Cancer Hospital in St. Louis, Mo.

That tiny amount of the radioisotope was purchased by the hospital for use in cancer studies. And it heralded a new peacetime mission for ORNL, built just a few years earlier for the production of plutonium from uranium for the Manhattan Project.

To continue reading, log in or create a free account!

Related Articles

X-energy begins irradiation testing at INL

November 12, 2025, 3:01PMNuclear News

Advanced reactor and fuel developer X-energy has officially begun confirmatory irradiation testing at Idaho National Laboratory on its TRISO-X fuel. The testing, which is taking place over the...

New financing round benefits Valar

November 13, 2025, 3:00PMNuclear News

Hawthorne, Calif.–based reactor start-up Valar Atomics recently announced that it has raised $130 million in its Series A funding round, led by venture capital groups Snowpoint, Day One, and...

ANS announces 2026 Presidential Citations

November 6, 2025, 6:59AMANS News

One of the privileges of being president of the American Nuclear Society is awarding Presidential Citations to individuals who have demonstrated outstanding effort in some manner for the...

NRC, DOE update MOU

November 5, 2025, 7:02AMNuclear News

The Nuclear Regulatory Commission and the Department of Energy have updated a 2019 memorandum of understanding to coordinate on the review of advanced nuclear reactors and advanced reactor...